Chair
Member
Chairman of the board
Financial expert
Audit Committee Position

Travis Coy is currently Vice President, Transactions - Oncology and Diagnostics, Corporate Business Development at Eli Lilly and Company. Prior to this role, Mr. Coy was responsible for leading and managing business development transactions for Lilly’s cardiometabolic disease, drug delivery, and device efforts. He has had a variety of finance and business development experiences at Lilly, including positions as Finance Director of Lilly’s Oncology Business Unit, Director of Investor Relations, Director of Corporate Finance and Investment Banking, and other financial controllership roles. Travis’ business development experiences have encompassed responsibilities ranging from managing the strategic and economic analyses of transactions to leading contract negotiations to having financial leadership of alliances. Before transitioning to finance and business development, he was a chemist in Lilly’s research laboratories and a production manager for Milliken & Company.

Chair

Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; Associate Cancer Center Director for Translational Research, Yale Cancer Center, New Haven, CT, USA

Member

Sid Kaul was appointed to the Immunocore Board of Directors as a Non-Executive Director in June 2022. Sid retired from Novartis as Group Treasurer and Head of Business Planning and Analysis in April 2021 after a 17 year career there. He led Novartis’s Strategic Review and Spin-Off for the Alcon (eye care) business. Sid joined Novartis as CFO Pharma Europe and subsequently served as CFO Pharma US following a 20-year career with Procter & Gamble in Financial Planning & Analysis, Strategic Planning, Accounting and Auditing in the US and Japan.

Member

Rob Perez is an Operating Partner and part of General Atlantic’s Operations Group, providing strategic support and advice to the firm’s investment team and portfolio companies with a particular focus on the biopharma and life sciences sectors. Before joining General Atlantic in 2019, he was Managing Director of Vineyard Sound Advisors, LLC, an advisory practice focused on growth companies in the biopharma industry. Prior to that, Rob was President and CEO of Cubist Pharmaceuticals, Inc. before its sale to Merck in 2015. Before joining Cubist in 2003, he served as Vice President of Biogen, Inc.’s CNS Business Unit.

Member

Professor Sir Peter Ratcliffe has over 30 years’ experience as a clinically active physician scientist. He currently serves as Director of Clinical Research at The Francis Crick Institute in London and Director of the Target Discovery Institute and Distinguished Scholar of the Ludwig Institute for Cancer Research within the Nuffield Department of Medicine at the University of Oxford. Sir Peter was elected to the Fellowship of the Royal Society and to the Academy of Medical Sciences in 2002. He is a member of European Molecular Biology Organization (EMBO), a foreign honorary member of the American Academy of Arts and Sciences and a Fellow of the American Association for Cancer Research (AACR) Academy. His work has been recognised through a number of awards, including the Louis‐Jeantet Prize in Medicine, the Canada Gairdner International Award, and the Lasker Award for Basic Biomedical Research. In 2019, he shared the Nobel Prize for Physiology or Medicine for discovery of the key mechanisms that cells use to detect and respond to hypoxia (low oxygen levels), opening up promising new ways to tackle cancer, anaemia and many other diseases. He was knighted for services to medicine in 2014.

Member

Audit Committee Charter

Download
Remuneration Committee Position

Kristine Peterson was appointed to the Immunocore Board of Directors as a Non-Executive Director in November 2017. Ms. Peterson has more than 30 years’ experience in the global pharmaceutical and biotech industry. Her most recent role was as Chief Executive Officer for Valeritas, Inc., where she led the company’s development from early stage R&D through to commercialisation, achieving approval by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the company’s Type 2 diabetes drug-device. In addition, Kristine raised more than $200 million in equity financing and prepared the company for its public listing on NASDAQ. Prior to Valeritas, Kristine was Company Group Chair at Johnson & Johnson for their worldwide biotech and oncology groups, growing those businesses to more than $6 billion in sales, launching several new products, and re-establishing the foundation for oncology R&D. She was also President and Senior Vice President, Commercial Operations for Biovail Corporation with responsibility for the US and Canadian business units. Earlier in her career, Kristine spent 20 years at Bristol-Myers Squibb in a variety of senior roles, including running their cardiovascular and metabolics business unit.

Kristine continues to play a role on several other Boards of Directors at pharmaceutical and biotech companies including Amarin Corporation, Paratek Pharmaceuticals, Enanta Pharmaceutics, pSivida, and ImmunoGen. She is also a senior advisor to the Healthcare Businesswomen’s Association and a former Member of the Biotechnology Industry Organization Board.

Chair

Professor Sir John Bell was appointed to the Immunocore Board in March 2015. Professor Bell is the Regius Professor of Medicine at Oxford University and Chairman of the Office for the Strategic Coordination of Health Research. He is regarded as one of the world’s most distinguished scientists in the fields of genomic and genetic research and immunology, also has significant experience in the Healthcare industry, having been a founding director at three biotechnology companies; Avidex Ltd (a precursor to Immunocore which was acquired by MediGene in 2006), Oxagen and PowderJect Pharmaceuticals plc (acquired by Chiron Corporation in 2003). He currently also serves on the boards of Roche and Genentech and had a previous role on the scientific advisory board at AstraZeneca. Professor Bell was involved in the founding of the Wellcome Trust Centre for Human Genetics at Oxford University, now chairs the scientific committee of UK Biobank and the Global Health Scientific Advisory Board of the Bill and Melinda Gates Foundation, and is one of three Life Science Champions for the UK, reporting to the UK Prime Minister. His research has contributed significantly to the understanding of immune activation in a number of auto-immune diseases.

Member

Travis Coy is currently Vice President, Transactions - Oncology and Diagnostics, Corporate Business Development at Eli Lilly and Company. Prior to this role, Mr. Coy was responsible for leading and managing business development transactions for Lilly’s cardiometabolic disease, drug delivery, and device efforts. He has had a variety of finance and business development experiences at Lilly, including positions as Finance Director of Lilly’s Oncology Business Unit, Director of Investor Relations, Director of Corporate Finance and Investment Banking, and other financial controllership roles. Travis’ business development experiences have encompassed responsibilities ranging from managing the strategic and economic analyses of transactions to leading contract negotiations to having financial leadership of alliances. Before transitioning to finance and business development, he was a chemist in Lilly’s research laboratories and a production manager for Milliken & Company.

Member

Sid Kaul was appointed to the Immunocore Board of Directors as a Non-Executive Director in June 2022. Sid retired from Novartis as Group Treasurer and Head of Business Planning and Analysis in April 2021 after a 17 year career there. He led Novartis’s Strategic Review and Spin-Off for the Alcon (eye care) business. Sid joined Novartis as CFO Pharma Europe and subsequently served as CFO Pharma US following a 20-year career with Procter & Gamble in Financial Planning & Analysis, Strategic Planning, Accounting and Auditing in the US and Japan.

Member

Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; Associate Cancer Center Director for Translational Research, Yale Cancer Center, New Haven, CT, USA

Member

Remuneration Committee Charter

Download
Nominating and Corporate Governance Committee Position

Rob Perez is an Operating Partner and part of General Atlantic’s Operations Group, providing strategic support and advice to the firm’s investment team and portfolio companies with a particular focus on the biopharma and life sciences sectors. Before joining General Atlantic in 2019, he was Managing Director of Vineyard Sound Advisors, LLC, an advisory practice focused on growth companies in the biopharma industry. Prior to that, Rob was President and CEO of Cubist Pharmaceuticals, Inc. before its sale to Merck in 2015. Before joining Cubist in 2003, he served as Vice President of Biogen, Inc.’s CNS Business Unit.

Chair

Professor Sir John Bell was appointed to the Immunocore Board in March 2015. Professor Bell is the Regius Professor of Medicine at Oxford University and Chairman of the Office for the Strategic Coordination of Health Research. He is regarded as one of the world’s most distinguished scientists in the fields of genomic and genetic research and immunology, also has significant experience in the Healthcare industry, having been a founding director at three biotechnology companies; Avidex Ltd (a precursor to Immunocore which was acquired by MediGene in 2006), Oxagen and PowderJect Pharmaceuticals plc (acquired by Chiron Corporation in 2003). He currently also serves on the boards of Roche and Genentech and had a previous role on the scientific advisory board at AstraZeneca. Professor Bell was involved in the founding of the Wellcome Trust Centre for Human Genetics at Oxford University, now chairs the scientific committee of UK Biobank and the Global Health Scientific Advisory Board of the Bill and Melinda Gates Foundation, and is one of three Life Science Champions for the UK, reporting to the UK Prime Minister. His research has contributed significantly to the understanding of immune activation in a number of auto-immune diseases.

Member

Kristine Peterson was appointed to the Immunocore Board of Directors as a Non-Executive Director in November 2017. Ms. Peterson has more than 30 years’ experience in the global pharmaceutical and biotech industry. Her most recent role was as Chief Executive Officer for Valeritas, Inc., where she led the company’s development from early stage R&D through to commercialisation, achieving approval by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the company’s Type 2 diabetes drug-device. In addition, Kristine raised more than $200 million in equity financing and prepared the company for its public listing on NASDAQ. Prior to Valeritas, Kristine was Company Group Chair at Johnson & Johnson for their worldwide biotech and oncology groups, growing those businesses to more than $6 billion in sales, launching several new products, and re-establishing the foundation for oncology R&D. She was also President and Senior Vice President, Commercial Operations for Biovail Corporation with responsibility for the US and Canadian business units. Earlier in her career, Kristine spent 20 years at Bristol-Myers Squibb in a variety of senior roles, including running their cardiovascular and metabolics business unit.

Kristine continues to play a role on several other Boards of Directors at pharmaceutical and biotech companies including Amarin Corporation, Paratek Pharmaceuticals, Enanta Pharmaceutics, pSivida, and ImmunoGen. She is also a senior advisor to the Healthcare Businesswomen’s Association and a former Member of the Biotechnology Industry Organization Board.

Member

Professor Sir Peter Ratcliffe has over 30 years’ experience as a clinically active physician scientist. He currently serves as Director of Clinical Research at The Francis Crick Institute in London and Director of the Target Discovery Institute and Distinguished Scholar of the Ludwig Institute for Cancer Research within the Nuffield Department of Medicine at the University of Oxford. Sir Peter was elected to the Fellowship of the Royal Society and to the Academy of Medical Sciences in 2002. He is a member of European Molecular Biology Organization (EMBO), a foreign honorary member of the American Academy of Arts and Sciences and a Fellow of the American Association for Cancer Research (AACR) Academy. His work has been recognised through a number of awards, including the Louis‐Jeantet Prize in Medicine, the Canada Gairdner International Award, and the Lasker Award for Basic Biomedical Research. In 2019, he shared the Nobel Prize for Physiology or Medicine for discovery of the key mechanisms that cells use to detect and respond to hypoxia (low oxygen levels), opening up promising new ways to tackle cancer, anaemia and many other diseases. He was knighted for services to medicine in 2014.

Member

Nominating and Corporate Governance Committee Charter

Download

Mr. Travis Coy

Travis Coy is currently Vice President, Transactions - Oncology and Diagnostics, Corporate Business Development at Eli Lilly and Company. Prior to this role, Mr. Coy was responsible for leading and managing business development transactions for Lilly’s cardiometabolic disease, drug delivery, and device efforts. He has had a variety of finance and business development experiences at Lilly, including positions as Finance Director of Lilly’s Oncology Business Unit, Director of Investor Relations, Director of Corporate Finance and Investment Banking, and other financial controllership roles. Travis’ business development experiences have encompassed responsibilities ranging from managing the strategic and economic analyses of transactions to leading contract negotiations to having financial leadership of alliances. Before transitioning to finance and business development, he was a chemist in Lilly’s research laboratories and a production manager for Milliken & Company.

Roy S. Herbst, MD, PhD

Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; Associate Cancer Center Director for Translational Research, Yale Cancer Center, New Haven, CT, USA

Siddharth (Sid) Kaul

Sid Kaul was appointed to the Immunocore Board of Directors as a Non-Executive Director in June 2022. Sid retired from Novartis as Group Treasurer and Head of Business Planning and Analysis in April 2021 after a 17 year career there. He led Novartis’s Strategic Review and Spin-Off for the Alcon (eye care) business. Sid joined Novartis as CFO Pharma Europe and subsequently served as CFO Pharma US following a 20-year career with Procter & Gamble in Financial Planning & Analysis, Strategic Planning, Accounting and Auditing in the US and Japan.

Mr. Rob Perez

Rob Perez is an Operating Partner and part of General Atlantic’s Operations Group, providing strategic support and advice to the firm’s investment team and portfolio companies with a particular focus on the biopharma and life sciences sectors. Before joining General Atlantic in 2019, he was Managing Director of Vineyard Sound Advisors, LLC, an advisory practice focused on growth companies in the biopharma industry. Prior to that, Rob was President and CEO of Cubist Pharmaceuticals, Inc. before its sale to Merck in 2015. Before joining Cubist in 2003, he served as Vice President of Biogen, Inc.’s CNS Business Unit.

Peter J. Ratcliffe

Professor Sir Peter Ratcliffe has over 30 years’ experience as a clinically active physician scientist. He currently serves as Director of Clinical Research at The Francis Crick Institute in London and Director of the Target Discovery Institute and Distinguished Scholar of the Ludwig Institute for Cancer Research within the Nuffield Department of Medicine at the University of Oxford. Sir Peter was elected to the Fellowship of the Royal Society and to the Academy of Medical Sciences in 2002. He is a member of European Molecular Biology Organization (EMBO), a foreign honorary member of the American Academy of Arts and Sciences and a Fellow of the American Association for Cancer Research (AACR) Academy. His work has been recognised through a number of awards, including the Louis‐Jeantet Prize in Medicine, the Canada Gairdner International Award, and the Lasker Award for Basic Biomedical Research. In 2019, he shared the Nobel Prize for Physiology or Medicine for discovery of the key mechanisms that cells use to detect and respond to hypoxia (low oxygen levels), opening up promising new ways to tackle cancer, anaemia and many other diseases. He was knighted for services to medicine in 2014.

Ms. Kristine Peterson

Kristine Peterson was appointed to the Immunocore Board of Directors as a Non-Executive Director in November 2017. Ms. Peterson has more than 30 years’ experience in the global pharmaceutical and biotech industry. Her most recent role was as Chief Executive Officer for Valeritas, Inc., where she led the company’s development from early stage R&D through to commercialisation, achieving approval by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the company’s Type 2 diabetes drug-device. In addition, Kristine raised more than $200 million in equity financing and prepared the company for its public listing on NASDAQ. Prior to Valeritas, Kristine was Company Group Chair at Johnson & Johnson for their worldwide biotech and oncology groups, growing those businesses to more than $6 billion in sales, launching several new products, and re-establishing the foundation for oncology R&D. She was also President and Senior Vice President, Commercial Operations for Biovail Corporation with responsibility for the US and Canadian business units. Earlier in her career, Kristine spent 20 years at Bristol-Myers Squibb in a variety of senior roles, including running their cardiovascular and metabolics business unit.

Kristine continues to play a role on several other Boards of Directors at pharmaceutical and biotech companies including Amarin Corporation, Paratek Pharmaceuticals, Enanta Pharmaceutics, pSivida, and ImmunoGen. She is also a senior advisor to the Healthcare Businesswomen’s Association and a former Member of the Biotechnology Industry Organization Board.

Professor Sir John Bell

Professor Sir John Bell was appointed to the Immunocore Board in March 2015. Professor Bell is the Regius Professor of Medicine at Oxford University and Chairman of the Office for the Strategic Coordination of Health Research. He is regarded as one of the world’s most distinguished scientists in the fields of genomic and genetic research and immunology, also has significant experience in the Healthcare industry, having been a founding director at three biotechnology companies; Avidex Ltd (a precursor to Immunocore which was acquired by MediGene in 2006), Oxagen and PowderJect Pharmaceuticals plc (acquired by Chiron Corporation in 2003). He currently also serves on the boards of Roche and Genentech and had a previous role on the scientific advisory board at AstraZeneca. Professor Bell was involved in the founding of the Wellcome Trust Centre for Human Genetics at Oxford University, now chairs the scientific committee of UK Biobank and the Global Health Scientific Advisory Board of the Bill and Melinda Gates Foundation, and is one of three Life Science Champions for the UK, reporting to the UK Prime Minister. His research has contributed significantly to the understanding of immune activation in a number of auto-immune diseases.

Mr. Travis Coy

Travis Coy is currently Vice President, Transactions - Oncology and Diagnostics, Corporate Business Development at Eli Lilly and Company. Prior to this role, Mr. Coy was responsible for leading and managing business development transactions for Lilly’s cardiometabolic disease, drug delivery, and device efforts. He has had a variety of finance and business development experiences at Lilly, including positions as Finance Director of Lilly’s Oncology Business Unit, Director of Investor Relations, Director of Corporate Finance and Investment Banking, and other financial controllership roles. Travis’ business development experiences have encompassed responsibilities ranging from managing the strategic and economic analyses of transactions to leading contract negotiations to having financial leadership of alliances. Before transitioning to finance and business development, he was a chemist in Lilly’s research laboratories and a production manager for Milliken & Company.

Siddharth (Sid) Kaul

Sid Kaul was appointed to the Immunocore Board of Directors as a Non-Executive Director in June 2022. Sid retired from Novartis as Group Treasurer and Head of Business Planning and Analysis in April 2021 after a 17 year career there. He led Novartis’s Strategic Review and Spin-Off for the Alcon (eye care) business. Sid joined Novartis as CFO Pharma Europe and subsequently served as CFO Pharma US following a 20-year career with Procter & Gamble in Financial Planning & Analysis, Strategic Planning, Accounting and Auditing in the US and Japan.

Roy S. Herbst, MD, PhD

Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; Associate Cancer Center Director for Translational Research, Yale Cancer Center, New Haven, CT, USA

Mr. Rob Perez

Rob Perez is an Operating Partner and part of General Atlantic’s Operations Group, providing strategic support and advice to the firm’s investment team and portfolio companies with a particular focus on the biopharma and life sciences sectors. Before joining General Atlantic in 2019, he was Managing Director of Vineyard Sound Advisors, LLC, an advisory practice focused on growth companies in the biopharma industry. Prior to that, Rob was President and CEO of Cubist Pharmaceuticals, Inc. before its sale to Merck in 2015. Before joining Cubist in 2003, he served as Vice President of Biogen, Inc.’s CNS Business Unit.

Professor Sir John Bell

Professor Sir John Bell was appointed to the Immunocore Board in March 2015. Professor Bell is the Regius Professor of Medicine at Oxford University and Chairman of the Office for the Strategic Coordination of Health Research. He is regarded as one of the world’s most distinguished scientists in the fields of genomic and genetic research and immunology, also has significant experience in the Healthcare industry, having been a founding director at three biotechnology companies; Avidex Ltd (a precursor to Immunocore which was acquired by MediGene in 2006), Oxagen and PowderJect Pharmaceuticals plc (acquired by Chiron Corporation in 2003). He currently also serves on the boards of Roche and Genentech and had a previous role on the scientific advisory board at AstraZeneca. Professor Bell was involved in the founding of the Wellcome Trust Centre for Human Genetics at Oxford University, now chairs the scientific committee of UK Biobank and the Global Health Scientific Advisory Board of the Bill and Melinda Gates Foundation, and is one of three Life Science Champions for the UK, reporting to the UK Prime Minister. His research has contributed significantly to the understanding of immune activation in a number of auto-immune diseases.

Ms. Kristine Peterson

Kristine Peterson was appointed to the Immunocore Board of Directors as a Non-Executive Director in November 2017. Ms. Peterson has more than 30 years’ experience in the global pharmaceutical and biotech industry. Her most recent role was as Chief Executive Officer for Valeritas, Inc., where she led the company’s development from early stage R&D through to commercialisation, achieving approval by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the company’s Type 2 diabetes drug-device. In addition, Kristine raised more than $200 million in equity financing and prepared the company for its public listing on NASDAQ. Prior to Valeritas, Kristine was Company Group Chair at Johnson & Johnson for their worldwide biotech and oncology groups, growing those businesses to more than $6 billion in sales, launching several new products, and re-establishing the foundation for oncology R&D. She was also President and Senior Vice President, Commercial Operations for Biovail Corporation with responsibility for the US and Canadian business units. Earlier in her career, Kristine spent 20 years at Bristol-Myers Squibb in a variety of senior roles, including running their cardiovascular and metabolics business unit.

Kristine continues to play a role on several other Boards of Directors at pharmaceutical and biotech companies including Amarin Corporation, Paratek Pharmaceuticals, Enanta Pharmaceutics, pSivida, and ImmunoGen. She is also a senior advisor to the Healthcare Businesswomen’s Association and a former Member of the Biotechnology Industry Organization Board.

Peter J. Ratcliffe

Professor Sir Peter Ratcliffe has over 30 years’ experience as a clinically active physician scientist. He currently serves as Director of Clinical Research at The Francis Crick Institute in London and Director of the Target Discovery Institute and Distinguished Scholar of the Ludwig Institute for Cancer Research within the Nuffield Department of Medicine at the University of Oxford. Sir Peter was elected to the Fellowship of the Royal Society and to the Academy of Medical Sciences in 2002. He is a member of European Molecular Biology Organization (EMBO), a foreign honorary member of the American Academy of Arts and Sciences and a Fellow of the American Association for Cancer Research (AACR) Academy. His work has been recognised through a number of awards, including the Louis‐Jeantet Prize in Medicine, the Canada Gairdner International Award, and the Lasker Award for Basic Biomedical Research. In 2019, he shared the Nobel Prize for Physiology or Medicine for discovery of the key mechanisms that cells use to detect and respond to hypoxia (low oxygen levels), opening up promising new ways to tackle cancer, anaemia and many other diseases. He was knighted for services to medicine in 2014.